A Multicentre, Randomised, Double-Blind Trial to Compare the Efficacy and Safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and Placebo in the Acute Treatment of AdultPatients with Migraine.

Study identifier:311CIL/0099

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicentre, Randomised, Double-Blind Trial to Compare the Efficacy and Safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and Placebo in the Acute Treatment of AdultPatients with Migraine.

Medical condition

migraine

Phase

N/A

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 1971

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2268&filename=CSR-311cil0099.pdf
Download
CSR-311cil0099.pdf
Download
Trial Results Summaries
Available here

A Multicentre, Randomised, Double-Blind Trial to Compare the Efficacy and Safety of ZOMIG 2.5 mg, NARAMIG 2.5 mg and Placebo in the Acute Treatment of AdultPatients with Migraine.

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2268&filename=CSR-311cil0099.pdf

CSR-311cil0099.pdf

Trial Results Summaries